Dual Marker Co-Expressed Exosome-Based Liquid Biopsy Electrochemical Assay for Enhanced-Accuracy Diagnosis of Prostate Cancer.

Authors

Feng Wei, Qingqing Jiang, Wenbai Chen, Fang Chen, Miaomiao Zhang, Yanyan Yu, Ming Guan, Shibao Li

Published in

ACS sensors. Jul 08, 2026. Epub Jul 08, 2026.

Abstract

Tumor-derived exosomes (TDEs) have emerged as clinically significant liquid biopsies for noninvasive early cancer diagnosis. Although serum prostate-specific antigens (PSA) are widely used for prostate cancer (PCa) screening, their diagnostic accuracy is compromised by elevated levels in nonmalignant conditions. B7H3, a protein overexpressed on cancer cell membranes, shows promise as a tumor diagnostic marker but lacks PCa specificity. To address these limitations, we developed an analytical platform for high-accuracy PCa screening via the co-recognition of dual exosomal markers (PSA and B7H3) using a paper-based electrochemical immunosensor. Magnetic Fe₃O₄ nanoparticles functionalized with multivalent PSA aptamers captured PSA⁺ TDEs, while anti-B7H3-conjugated iron-manganese silicate nanozymes (IMSNs) amplified the electrochemical signals. A specific electrochemical response occurred only when both markers were highly expressed on TDEs, eliminating false positives from inflammation-induced PSA elevation. Coupled with high sensitivity (detection limit: 81 particles/mL) and specificity for TDEs detection, the assay successfully screened 50 PCa patients, 33 benign prostatic hyperplasia (BPH) patients, and 20 healthy controls, enabling enhanced-accuracy diagnosis of PCa.

PMID:
42418184
Bibliographic data and abstract were imported from PubMed on 08 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.